West Pharmaceutical Services Reports Director & Officer Changes

Ticker: WST · Form: 8-K · Filed: Sep 11, 2025 · CIK: 105770

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

TL;DR

WEST board shakeup and comp changes filed. Watch for new exec strategy.

AI Summary

On September 11, 2025, West Pharmaceutical Services, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in corporate governance and potential adjustments to how key personnel are compensated.

Why It Matters

Changes in a company's board of directors and executive compensation can signal shifts in strategic direction or financial priorities, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in directorship and executive compensation can indicate underlying strategic shifts or internal dynamics that may affect future performance.

Key Numbers

Key Players & Entities

FAQ

What specific changes were made to the board of directors?

The filing indicates 'Departure of Directors or Certain Officers; Election of Directors' as an item of disclosure, but the specific names and details of departures or elections are not provided in this excerpt.

What are the details of the compensatory arrangements for certain officers?

The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not included in the provided text.

What is the company's principal executive office address?

The address of the principal executive offices is 530 Herman O. West Drive, Exton, PA 19341-1147.

When was the company incorporated?

The company was incorporated in Pennsylvania.

What is the SIC code for West Pharmaceutical Services, Inc.?

The Standard Industrial Classification (SIC) code is 3841 for SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-11 16:06:19

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 104 The cover page from the Company's Current Report on Form 8-K, dated September 11, 2025, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2025 WEST PHARMACEUTICAL SERVICES, INC. By: /s/ Chad R. Winters Chad R. Winters Vice President, Finance & Chief Accounting Officer 3 EXHIBIT INDEX Exhibit No. Description 104 The cover page from the Company's Current Report on Form 8-K, dated September 11, 2025, formatted in Inline XBRL. 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing